NASDAQ: SYRE Spyre Therapeutics, Inc. 8-K

Spyre expands SPY003 license to all therapeutic uses, but faces dosing delays until 2030

Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SYRE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 8:05 PM